Cholesterol Absorption Inhibition Study (CASTELL)
CASTELL = Cholesterol Absorption Study STErols (LL)
Rationale: Consuming Plant Sterols (PS) fortified foods is widely accepted as easy to apply, life-style change to combat modestly elevated plasma cholesterol concentrations. PS are typically formulated as PS fatty acid ester (PSE) from margarines. In this study, PS will be formulated in a new innovative type spread. To confirm that the new spread results in a comparable cholesterol absorption inhibition as the reference product a dual isotope cholesterol study is planned, prior to any larger efficacy study.
Primary objective: Cholesterol absorption inhibition (%) calculated from plasma concentration vs. time curves from labeled cholesterol, for the PS or PSE containing products, compared to a control product without PS or PSE.
Secondary objectives: PK parameters for cholesterol as derived from the plasma concentration vs. time curves.
Study design: Acute, single dose, double-blind, randomized, cross-over. Study population: 18 healthy, non-obese men (BMI 20-27 kg∙m-2, age range 20 - 65 yr) Test products: PS (2250 mg) formulated in innovatively processed spread (30 g); PSE (2250 mg PS) reference product (30 g); Control product without PS or PSE (30 g) Intervention: Three study periods during which a single dose of either Test, Reference or Control (regular light spread) spreads will be consumed together with standard breakfast. At each study period, 50 mg of D7-cholesterol is added to the meal and 30 mg of 13C-cholesterol is injected to measure cholesterol absorption. Before and four times after consumption of each spread, blood samples will be taken at 24 h intervals up to 7 days.
Key parameters: Enrichments of labeled cholesterol isotopes as determined by GCMS and IRMS. Fractional absorption is determined by the ratio of the two isotopes in plasma cholesterol after 7 days.
調査の概要
状態
状態
条件
条件
介入・治療
介入・治療
研究の種類
研究の種類
入学 (予想される)
入学
段階
段階
- 適用できない
連絡先と場所
研究場所
-
-
Noord-Holland
-
Amsterdam、Noord-Holland、オランダ
- Academisch Medisch Centrum, vasculaire geneeskunde
-
-
参加基準
適格基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Apparently healthy: no medical conditions which might effect study measurements (judged by study physician).
- Males aged 20 - 65
- BMI 20-27 kg∙m-2
- LDL-C levels between 3.0 - 5.0 mmol/L, triglycerides < 3.0 mmol/L
- Not more than 10 hours per week of strenuous exercise
- Ability to give informed consent.
- Ability to follow verbal and written instructions.
- Non-smoker (tobacco, marijuana).
- The ability to attend and to commute to the performance site for each of study day visit and follow-up throughout the study period are required.
- Willing to consume a breakfast in the morning of each study day.
- Willing to consume margarine on each study occasion.
- Having a general practitioner.
- No use of medication which interferes with study measurements (as judged by the study physician).
- Agreeing to be informed about medically relevant personal test-results after the screening visit by a physician.
- Consumption =< 21 alcoholic drinks in a typical week.
- No blood donation 1 month prior to pre-study examination or during the study.
- Has accessible veins on the forearm as determined by examination at screening.
- Not being an employee of Unilever.
- No reported participation in another nutritional or biomedical trial 3 months before the pre-study examination or during the study.
No reported participation in night shift work during the study.
Exclusion Criteria:
- Unwilling to refrain from consumption of plant sterol or stanol containing products one week before and during the study..
- Plasma lipid profile which indicates deviating lipid / cholesterol homeostasis, to be judged by study physician.
- Evidence of severe cardiovascular, respiratory, urogenital, gastrointestinal/ hepatic, hemato¬logical/ immunologic, HEENT (head, ears, eyes, nose, throat), dermatological/ connective tissue, musculoskeletal, metabolic/nutritional, endocrine, neurological/ psychiatric diseases, allergy, major surgery and/or laboratory assessments which might limit participation in or completion of the study protocol.
- Gastrointestinal or hepatic disorders influencing gastrointestinal absorption or transit, including gallstones or biliary diseases.
- History of surgery related to the gastro-intestinal tract
- On a medically prescribed or weight reduction diet
- Recreational (intravenous) drug use.
- The use of psychotropic drugs, including: benzodiazepines or alcohol in excess of 21 units/ week for males
- Concomitant medication that may modulate gastro-intestinal secretions and pH (e.g. antacids, proton-pump-inhibitors, prostaglandins, anticholinergic agents, H2-receptor antagonists)
- Concomitant medication that can alter gastric emptying (e.g. metoclopramide, cisapride, domperidone and erythromycin, anticholinergics, tricyclic antidepressants, narcotic analgesics, adrenergic agents, calcium channel blockers)
- Concomitant medication that can alter intestinal transit (e.g. loperamide, chemical/ osmotic/bulk laxatives), or influence satiety/energy intake (e.g. sibutramine, gluco¬corticoids, anabolic steroids)
- Intolerance or allergy for test product.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:防止
- 割り当て:ランダム化
- 介入モデル:クロスオーバー割り当て
- マスキング:トリプル
アーム数
武器と介入
参加者グループ / アーム参加者グループ / アーム |
介入・治療介入・治療 |
|---|---|
|
アクティブコンパレータ:Reference spread
2250 mg PS (as PSE) in spread (30 g)
|
Single dose (30 gr) of spread, containing 2250 mg PS
|
|
プラセボコンパレーター:Placebo spread
regular light margarine (30 g)
|
Single dose (30 gr) of regular light margarine
|
|
実験的:Test spread
2250 mg PS in innovatively processed spread (30 g)
|
Single dose (30 gr) of innovatively processed spread containing 2250 mg PS.
|
この研究は何を測定していますか?
主要な結果の測定
主要な結果の測定
結果測定 |
時間枠 |
|---|---|
|
cholesterol absorption calculated from plasma cholesterol enrichments vs. time curves
時間枠:5 blood samples within one week for each intervention
|
5 blood samples within one week for each intervention
|
二次結果の測定
二次結果の測定
結果測定 |
時間枠 |
|---|---|
|
PK parameters derived from plasma curves (Cmax, Tmax, cholesterol pool, flux).
時間枠:5 blood samples within one week for each intervention
|
5 blood samples within one week for each intervention
|
協力者と研究者
協力者
協力者
捜査官
捜査官
- 主任研究者:Maud N Vissers, Dr. Ir、Academisch Medisch Centrum, afdeling vasculaire geneeskunde
- スタディディレクター:Guus SM Duchateau, Dr、Unilever Research & Development Vlaardingen
研究記録日
主要日程の研究
研究開始
研究開始
一次修了 (実際)
一次修了
研究の完了 (実際)
研究の完了
試験登録日
最初に提出
最初に提出
QC基準を満たした最初の提出物
QC基準を満たした最初の提出物
最初の投稿 (見積もり)
最初の投稿
学習記録の更新
投稿された最後の更新 (実際)
投稿された最後の更新
QC基準を満たした最後の更新が送信されました
QC基準を満たした最後の更新が送信されました
最終確認日
最終確認日
詳しくは
本研究に関する用語
その他の研究ID番号
その他の研究ID番号
- 09030V
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。